Philogen Updates Share Buyback Program with Recent Purchases

Philogen SpA ( (IT:PHIL) ) has shared an announcement.

Philogen S.p.A. has updated its share buyback program, purchasing 3,872 shares from March 3 to March 7, 2025, representing 0.0095% of its share capital at an average price of Euro 18.6767 per share. This move is part of a broader strategy, with the company having acquired a total of 33,097 shares since the program’s inception, amounting to 0.0815% of its share capital. The buyback program is indicative of Philogen’s efforts to enhance shareholder value and maintain a strong market position in the biotechnology sector.

More about Philogen SpA

Philogen is an Italian-Swiss biotechnology company specializing in the research and development of pharmaceutical products aimed at treating high-mortality diseases. The company focuses on creating targeted anti-cancer drugs using high-affinity ligands for tumor markers, primarily through technologies like Antibody Phage Display Libraries and DNA-Encoded Chemical Libraries. Philogen’s main therapeutic strategy involves tumor targeting, which selectively delivers potent therapeutic agents to tumors while sparing healthy tissues. The company aims to develop and commercialize innovative treatments for diseases lacking satisfactory therapies, with a focus on oncological applications and potential applicability to chronic inflammatory diseases.

YTD Price Performance: -7.11%

Average Trading Volume: 317

Technical Sentiment Consensus Rating: Buy

Current Market Cap: €542.5M

See more data about PHIL stock on TipRanks’ Stock Analysis page.